PBLS (Parabilis Medicines) EV-to-OCF: (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBLS Parabilis Medicines Inc PBLS
10 GF Score
Price $31.43
! 1 Warning Sign
View Full Analysis

What is Parabilis Medicines EV-to-OCF?

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Parabilis Medicines's Enterprise Value is $4,382.93 Mil. Parabilis Medicines does not have enough years/quarters to calculate its Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Parabilis Medicines's EV-to-OCF at this moment.

The historical rank and industry rank for Parabilis Medicines's EV-to-OCF or its related term are showing as below:

PBLS' s EV-to-OCF Range Over the Past 10 Years
Min: -36.82   Med: 0   Max: -34.39
Current: -35.43

During the past 2 years, the highest EV-to-OCF of Parabilis Medicines was -34.39. The lowest was -36.82. And the median was .

PBLS's EV-to-OCF is ranked better than
89.29% of 1410 companies
in the Biotechnology industry
Industry Median: -3.315 vs PBLS: -35.43

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-24), Parabilis Medicines's stock price is $31.43. Parabilis Medicines does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Parabilis Medicines's PE Ratio (TTM) at this moment.

Parabilis Medicines  (NAS:PBLS) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Parabilis Medicines's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=31.43/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Parabilis Medicines EV-to-OCF Related Terms

Parabilis Medicines EV-to-OCF Historical Data

* Premium members only.

The historical data trend for Parabilis Medicines's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parabilis Medicines EV-to-OCF Chart

Parabilis Medicines Annual Data
Trend Dec24 Dec25
EV-to-OCF
0.00 0.00

Parabilis Medicines Semi-Annual Data
Dec24 Dec25
EV-to-OCF 0.00 0.00

PBLS vs IDYA, ELVN, BEAM: EV-to-OCF Comparison

For the Biotechnology subindustry, Parabilis Medicines's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parabilis Medicines EV-to-OCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Parabilis Medicines's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where Parabilis Medicines's EV-to-OCF falls into.


PBLS
10GF Score
Parabilis Medicines Inc PBLS
EV-to-OCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parabilis Medicines EV-to-OCF Calculation

Parabilis Medicines's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=4382.925/
=

Parabilis Medicines Business Description

Address 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score

Get the complete analysis for PBLS

EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.43
Price